Skip to content
value.today

Kyverna Therapeutics, Inc.

KYTX
$341 Mmarket cap on Oct 26, 2026
Compare
World rank
#14,253
Revenue
—
For year ending December-2025
Net income
$-161 M
SEC filing
Employees
130
As of March 1, 2026
SEC filing

Kyverna Therapeutics, Inc. in brief

Kyverna Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Emeryville, California, USA. Its market value was $341 M on 26 October 2026, which makes it the 14,253rd largest listed company in the world and the 2,792nd largest in the USA on this site. It employs about 130 people and Warner Weston Biddle is its chief executive. Its shares trade under the symbol KYTX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Kyverna Therapeutics, Inc.

We are a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Our mission is to liberate patients from autoimmune diseases through the curative potential of cell therapy. Our development strategy is supported by our breadth of experience in treating more than 100 autoimmune patients with our lead product candidate, mivocabtagene autoleucel, or miv-cel, also known as KYV-101, an anti-CD19 autologous CAR T with a differentiated CAR construct. This has been documented through the scientific publication of multiple autoimmune case studies, our proprietary dataset of patients treated through named patient forms of compassionate use, our experience in ongoing investigator-initiated trials, or IITs, at leading academic institutions, as well as early clinical data from our ongoing company-sponsored trials illustrating the potential of these therapies to deeply deplete B cells with the aim of achieving durable treatment-free remission. This validation provides us with a clear path to continue advancing miv-cel through late-stage clinical development and commercialization across multiple autoimmune indications.

From the company's annual report filed with the US SEC: read the report

Kyverna Therapeutics, Inc. timeline

2 events, 2023–2024
  1. 2023
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2024
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 8 February 2024; shares registered for exchange trading on 5 February 2024.

Events of Kyverna Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$136 M$273 M$409 M$545 M

World rank over time

▼ down 2,056 places since 2026
2026-08-01: #12231#12,23120262026-10-13: #13709#13,70920262026-10-26: #14287#14,2872026

Rank in USA: #2,535 (Aug 2026) · #2,674 (Oct 2026) · #2,796 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.5×
Free cash flow yield
-45.1%
Net margin
—
Operating margin
—
Return on equity
-69.4%
Liabilities / assets
20.9%
Net debt
$-99M
Profit per employee
$-1.2 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2023: revenue —, net income $-60M—FY23Fiscal year ending Dec 2024: revenue —, net income $-127M—FY24Fiscal year ending Dec 2025: revenue —, net income $-161M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-170M$-161M—
Dec 2024——$-143M$-127M—
Dec 2023——$-62M$-60M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-154M$0M$-154M$-3.64—
Dec 2024$-114M$2M$-116M$-3.33—
Dec 2023$-52M$1M$-53M$-89.61—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-38M—Dec ’24Three months to Mar 2025: revenue —, net income $-45M—Mar ’25Three months to Jun 2025: revenue —, net income $-42M—Jun ’25Three months to Sep 2025: revenue —, net income $-37M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-38M—Dec ’25Three months to Mar 2026: revenue —, net income $-40M—Mar ’26Three months to Jun 2026: revenue —, net income $-38M—Jun ’26Three months to Sep 2026: revenue —, net income $-42M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-42M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Kyverna Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-170 M
Net income
$-161 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$294 M
Total liabilities
$62 M
Total equity
$232 M

As of December-2025

Top 100 institutional investors in Kyverna Therapeutics, Inc.#

As of Sep 30, 2026
128 institutions held 35.2 M shares (about 55.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 36.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Kyverna Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1GordonMD Global Investments LP4,521,318+276,500 (+6.51%)7.15%$31 MNov 16, 2026
2Gilead Sciences, Inc.4,126,1190 (0.00%)6.53%$28 MNov 6, 2026
3AIGH Capital Management LLC3,650,000+854,203 (+30.55%)5.77%$25 MNov 2, 2026
4BlackRock, Inc.3,238,110+103,303 (+3.30%)5.12%$22 MNov 13, 2026
5Vanguard Capital Management LLC2,011,138+113,687 (+5.99%)3.18%$14 MNov 13, 2026
6Bain Capital Life Sciences Investors, LLC1,312,000-1,573,000 (-54.52%)2.08%$9 MNov 16, 2026
7Price T Rowe Associates Inc /MD/1,207,564+21,541 (+1.82%)1.91%$8 MNov 16, 2026
8State Street Corp1,203,252+221,019 (+22.50%)1.90%$8 MNov 12, 2026
9Geode Capital Management, LLC1,053,681+4,251 (+0.41%)1.67%$7 MNov 6, 2026
10Insight Holdings Group, LLC989,0540 (0.00%)1.56%$7 MNov 16, 2026
11Millennium Management LLC826,137+186,357 (+29.13%)1.31%$6 MNov 16, 2026
12Propel Bio Management, LLC700,595-182,603 (-20.68%)1.11%$5 MNov 13, 2026
13MBB Public Markets I LLC614,4770 (0.00%)0.97%$4 MNov 16, 2026
14UBS Group AG599,284+233,710 (+63.93%)0.95%$4 MNov 10, 2026
15Morgan Stanley552,246-430,061 (-43.78%)0.87%$4 MNov 13, 2026
16Goldman Sachs Group Inc551,899+216,669 (+64.63%)0.87%$4 MNov 16, 2026
17FMR LLC538,379+442,328 (+460.51%)0.85%$4 MNov 10, 2026
18Adage Capital Partners GP, L.L.C.500,0000 (0.00%)0.79%$3 MNov 16, 2026
19Wells Fargo & Company/mn461,796+88,787 (+23.80%)0.73%$3 MNov 16, 2026
20Woodline Partners LP423,325-422,000 (-49.92%)0.67%$3 MNov 16, 2026
21Vanguard Portfolio Management LLC360,489+78,300 (+27.75%)0.57%$2 MNov 13, 2026
22Charles Schwab Investment Management Inc333,505+13,839 (+4.33%)0.53%$2 MNov 16, 2026
23Renaissance Technologies LLC327,821-6,078 (-1.82%)0.52%$2 MNov 12, 2026
24Northern Trust Corp325,011+9,657 (+3.06%)0.51%$2 MNov 16, 2026
25Dimensional Fund Advisors LP278,566+200,147 (+255.23%)0.44%$2 MNov 4, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Kyverna Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26BNP Paribas Financial Markets276,016-34,616 (-11.14%)0.44%$2 MNov 12, 2026
27Vanguard Fiduciary Trust Co259,506-161 (-0.06%)0.41%$2 MNov 13, 2026
28Nuveen, LLC239,940+6,197 (+2.65%)0.38%$2 MNov 10, 2026
29Burkehill Global Management, LP200,0000 (0.00%)0.32%$1 MNov 16, 2026
30Point72 Asset Management, L.P.186,902New0.30%$1 MNov 16, 2026
31Simplify Asset Management Inc.182,6030 (0.00%)0.29%$1 MOct 27, 2026
32Susquehanna International Group, LLP157,535+1,735 (+1.11%)0.25%$1 MNov 16, 2026
33D. E. Shaw & Co., Inc.146,890-322,456 (-68.70%)0.23%$1 MNov 16, 2026
34Wellington Management Group LLP146,346+28,904 (+24.61%)0.23%$1 MNov 16, 2026
35TD Asset Management Inc145,6820 (0.00%)0.23%$1 MNov 13, 2026
36Stifel Financial Corp139,922-43 (-0.03%)0.22%$1 MNov 12, 2026
37Citadel Advisors LLC137,034-10,593 (-7.18%)0.22%$1 MNov 16, 2026
38Barclays PLC136,134+18,290 (+15.52%)0.22%$1 MNov 6, 2026
39Raymond James Financial Inc128,993New0.20%$1 MNov 12, 2026
40Bank of New York Mellon Corp104,452+4,171 (+4.16%)0.17%$1 MNov 5, 2026
41Manufacturers Life Insurance Company, The100,700+18,493 (+22.50%)0.16%$1 MNov 13, 2026
42Nano Cap New Millennium Growth Fund L P90,000+20,000 (+28.57%)0.14%$1 MNov 13, 2026
43Susquehanna Portfolio Strategies, LLC87,210-1,635 (-1.84%)0.14%$1 MNov 16, 2026
44Susquehanna Fundamental Investments, LLC83,918+38,558 (+85.00%)0.13%$1 MNov 16, 2026
45Franklin Templeton Inc77,996New0.12%$1 MNov 12, 2026
46Marshall Wace, LLP73,276New0.12%$0 MNov 13, 2026
47Invesco Ltd.73,001+17,194 (+30.81%)0.12%$0 MNov 12, 2026
48Man Group plc71,918+3,278 (+4.78%)0.11%$0 MNov 16, 2026
49Aquatic Capital Management LLC71,814New0.11%$0 MNov 16, 2026
50American Century Companies Inc70,062+711 (+1.03%)0.11%$0 MNov 12, 2026
51Rhumbline Advisers54,137+3,949 (+7.87%)0.09%$0 MNov 10, 2026
52XTX Topco Ltd45,060+23,162 (+105.77%)0.07%$0 MNov 16, 2026
53Bank Of America Corp /de/44,984-220,421 (-83.05%)0.07%$0 MNov 16, 2026
54Canada Pension Plan Investment Board44,700+4,700 (+11.75%)0.07%$0 MNov 16, 2026
55Banque Cantonale Vaudoise40,000+6,556 (+19.60%)0.06%$0 MNov 12, 2026
56ACT Capital Partners, L.P.40,000—0.06%$0 MNov 6, 2026
57Deutsche Bank AG\39,736-5,117 (-11.41%)0.06%$0 MNov 6, 2026
58Kera Capital Partners, Inc.35,000-5,000 (-12.50%)0.06%$0 MNov 13, 2026
59PDT Partners, LLC31,902New0.05%$0 MNov 16, 2026
60IFP Advisors, Inc29,000+16,500 (+132.00%)0.05%$0 MOct 16, 2026
61Bridgeway Capital Management, LLC27,583-122,317 (-81.60%)0.04%$0 MNov 16, 2026
62Vanguard Global Advisers, LLC26,751+11,762 (+78.47%)0.04%$0 MNov 13, 2026
63Mitsubishi UFJ Asset Management Co., Ltd.25,528-213 (-0.83%)0.04%$0 MNov 5, 2026
64MetLife Investment Management, LLC25,222-403 (-1.57%)0.04%$0 MNov 16, 2026
65Jpmorgan Chase & Co24,887+1,903 (+8.28%)0.04%$0 MNov 12, 2026
66Y-Intercept (Hong Kong) Ltd24,811-217,576 (-89.76%)0.04%$0 MOct 16, 2026
67Los Angeles Capital Management LLC22,531+13,948 (+162.51%)0.04%$0 MNov 12, 2026
68Alliancebernstein L.P.22,1000 (0.00%)0.04%$0 MNov 16, 2026
69Federated Hermes, Inc.22,000-8,705 (-28.35%)0.03%$0 MNov 12, 2026
70Two Sigma Investments, LP21,575-29,744 (-57.96%)0.03%$0 MNov 16, 2026
71MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.20,262+1,022 (+5.31%)0.03%$0 MNov 16, 2026
72Brevan Howard Capital Management LP20,144New0.03%$0 MNov 16, 2026
73Phoenix Wealth Advisors19,8000 (0.00%)0.03%$0 MNov 3, 2026
74DRW Securities, LLC19,325New0.03%$0 MNov 13, 2026
75Empowered Funds, LLC18,683New0.03%$0 MNov 13, 2026
76Creative Planning18,020New0.03%$0 MNov 2, 2026
77Tower Research Capital LLC (TRC)17,893+15,540 (+660.43%)0.03%$0 MNov 16, 2026
78Vanguard Personalized Indexing Management, LLC16,827-1,160 (-6.45%)0.03%$0 MNov 16, 2026
79AQR Capital Management LLC16,380New0.03%$0 MNov 16, 2026
80Corient Private Wealth LP16,000New0.03%$0 MNov 16, 2026
81Savant Capital, LLC15,092New0.02%$0 MNov 6, 2026
82Baldwin Wealth Partners Llc/ma13,969New0.02%$0 MOct 13, 2026
83Engineers Gate Manager LP13,742New0.02%$0 MNov 16, 2026
84&partners13,065New0.02%$0 MNov 16, 2026
85Police & Firemen's Retirement System of New Jersey12,3760 (0.00%)0.02%$0 MNov 9, 2026
86Caxton Corp12,3470 (0.00%)0.02%$0 MNov 16, 2026
87Ethic Inc.12,261+438 (+3.70%)0.02%$0 MNov 3, 2026
88WINTON GROUP Ltd11,800-5,600 (-32.18%)0.02%$0 MNov 12, 2026
89Samalin Investment Counsel, LLC11,5950 (0.00%)0.02%$0 MOct 23, 2026
90Oppenheimer & Co Inc11,500New0.02%$0 MOct 26, 2026
91China Universal Asset Management Co., Ltd.11,284+1,608 (+16.62%)0.02%$0 MOct 28, 2026
92Simplex Trading, LLC11,175New0.02%$0 MNov 4, 2026
93HSBC Holdings PLC11,166New0.02%$0 MNov 16, 2026
94North Star Investment Management Corp.10,000New0.02%$0 MOct 27, 2026
95Grey Ledge Advisors, LLC10,0000 (0.00%)0.02%$0 MNov 2, 2026
96Kovack Advisors, Inc.10,000New0.02%$0 MNov 13, 2026
97New York State Common Retirement Fund9,0000 (0.00%)0.01%$0 MNov 17, 2026
98Royal Bank Of Canada7,623+746 (+10.85%)0.01%$0 MNov 16, 2026
99Osaic Holdings, Inc.5,295+1,355 (+34.39%)0.01%$0 MNov 12, 2026
100Zurcher Kantonalbank (Zurich Cantonalbank)4,962+1,849 (+59.40%)0.01%$0 MNov 10, 2026

All 128 institutional investors, with who bought and sold →

Mutual funds holding Kyverna Therapeutics, Inc.#

93 funds hold shares worth $65 M (about 12.0% of the company). Since their previous reports 78 added shares and 5 sold, buying $29 M net.
Mutual funds holding Kyverna Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.40 M$13 M2.2%<0.01%+4.2%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.07 M$10 M1.7%0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.856,798$8 M1.4%0.06%−25%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.448,147$4 M0.71%<0.01%+13%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC458,351$3 M0.72%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors352,088$3 M0.56%0.02%newJun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors266,211$2 M0.42%0.03%+5.9%Jun 30, 2026
🇺🇸 State Street SPDR S&P Kensho New Economies Composite ETFSSGA Funds Management, Inc.260,625$2 M0.41%0.08%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC183,789$2 M0.29%<0.01%+56%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.167,964$1 M0.27%<0.01%+51%May 31, 2026
🇺🇸 Invesco Dorsey Wright SmallCap Momentum ETFInvesco Capital Management LLC166,182$1 M0.26%0.34%newMay 31, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC177,936$1 M0.28%<0.01%newJul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors139,400$1 M0.22%0.08%+45%Jun 30, 2026
🇺🇸 WesMark Small Company FundWESBANCO INVESTMENT DEPARTMENT110,300$1 M0.17%0.53%no changeJun 30, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC87,942$1 M0.14%0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.106,199$1 M0.17%0.08%newJul 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.102,479$1 M0.16%<0.01%newJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC78,440$1 M0.12%0.01%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust65,620$1 M0.10%0.02%+32%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC64,591$1 M0.10%<0.01%+60%May 31, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.55,173$0 M0.09%0.07%−32%Jun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC53,721$0 M0.08%0.02%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC53,664$0 M0.08%<0.01%+69%May 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC55,807$0 M0.09%0.01%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC45,656$0 M0.07%0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P.46,835$0 M0.07%0.03%newJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC37,959$0 M0.06%<0.01%+18%May 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors34,167$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation30,600$0 M0.05%0.01%newJun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC29,000$0 M0.05%0.17%no changeJun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP31,215$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC30,651$0 M0.05%<0.01%+70%Jul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.23,148$0 M0.04%<0.01%+37%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.22,459$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.21,684$0 M0.03%0.01%newJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.25,000$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC17,518$0 M0.03%0.06%−45%Jun 30, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.16,677$0 M0.03%0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC20,135$0 M0.03%<0.01%+9.9%Jul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC19,945$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC16,050$0 M0.03%0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC14,522$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.15,000$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.13,931$0 M0.02%0.05%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.13,600$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP15,873$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS12,296$0 M0.02%0.05%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC12,058$0 M0.02%0.01%newJun 30, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC11,854$0 M0.02%0.06%−48%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC14,109$0 M0.02%<0.01%+14%Jul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.9,911$0 M0.02%<0.01%+13%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC9,398$0 M0.01%0.04%+38%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS9,371$0 M0.01%0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC8,933$0 M0.01%0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC7,710$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC7,710$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP9,116$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.6,581$0 M0.01%0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.6,327$0 M0.01%0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC7,476$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC6,016$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P.7,006$0 M0.01%0.02%newJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC5,694$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP6,614$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC5,077$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC6,020$0 M<0.01%0.01%+13%Jul 31, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC5,270$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC4,914$0 M<0.01%0.01%newJul 31, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP4,825$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management3,808$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP4,410$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.4,360$0 M<0.01%<0.01%+15%Jul 31, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP4,308$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC3,452$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC3,355$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC3,219$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust3,361$0 M<0.01%0.02%no changeMay 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS3,729$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC2,914$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP3,349$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC2,577$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC2,686$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,950$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC1,828$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,470$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS1,648$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,059$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,009$0 M<0.01%<0.01%+28%Jun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC869$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC841$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC517$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC278$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC267$0 M<0.01%<0.01%+14%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 93 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Kyverna Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$1000 K
2 purchases, 2 insiders
Sold, 12 months
$293 K
1 sale, 1 insider
Net, 12 months
$707 K
open market only
Insiders on file
19
since
$35.5 M-$293 K$0Feb 2024: bought $35.5 M (5 trades), sold $0 (0 trades)Feb 24Dec 2025: bought $1000 K (2 trades), sold $293 K (1 trades)Dec
Bought (open market)Sold (open market)Hover a month for the totals
Kyverna Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Fred E. CohenDirectorGrant or award+5,093——21,727Form 4
filed Ian T. ClarkDirectorGrant or award+5,093——21,727Form 4
filed Beth C. SeidenbergDirectorGrant or award+5,093——21,727Form 4
filed Christi ShawExecutive Chairperson, DirectorShares withheld for tax-4,194$8.590$36 K66,741Form 4
filed Mert AktarDirectorGrant or award+5,093——21,727Form 4
filed Warner Weston BiddleChief Executive Officer, DirectorGrant or award+58,000——58,000Form 4
filed Naji GehchanSee RemarksGrant or award+18,000——18,000Form 4
filed Marc GrassoChief Financial OfficerGrant or award+10,000——10,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Kyverna Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
9.1 M
15.1% of shares · 11.6 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-4.57 reverse split

Trading halts

  • 2025-12-15 14:54 UTC, code LUDP, resumed 14:59 UTC

Fails to deliver

  • : 7,241 shares at $5.39
  • : 4,892 shares at $5.67
  • : 9,458 shares at $5.97
  • : 4,660 shares at $5.69
  • : 3,428 shares at $6.21

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Kyverna Therapeutics, Inc. scorecard#

Passes 4 of the 12 checks that could be worked out: strongest in financial health (3 of 4), weakest in valuation (1 of 4). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.5×Price to book 1.5× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-45.1%Free cash flow is -45.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-3.64 vs -3.33Diluted EPS -3.64 in fiscal 2025 against -3.33 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$161 MNet income -$161 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-64.7%-64.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 4
    • ✓Short-term assets cover short-term liabilities7.8×Current ratio 7.75 at the end of fiscal 2025.
    • ✓Debt below equity0.1×Debt to equity 0.11 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $99 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year15.5%Diluted shares up 15.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Kyverna Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Kyverna Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023
Income statement
Research and development13411250
General and administrative363012
Operating expenses17014362
Operating income−170−143−62
Interest and finance income9.1152.3
Interest expense and finance costs0.50.10.2
Other non-operating income (expense)8.5152.0
Income tax000
Net income attributable to shareholders−161−127−60
Earnings per share, basic-3.64-3.33-89.61
Earnings per share, diluted-3.64-3.33-89.61
Shares, weighted average (basic)44380.7
Shares, weighted average (diluted)44380.7
Balance sheet
Cash and cash equivalents1249735
Short-term investments15518923
Other current assets3.74.63.1
Current assets28329161
Property, plant and equipment1.53.32.3
Right-of-use (leased) assets3.66.56.5
Total assets29430575
Accounts payable5.34.64.4
Current liabilities363420
Long-term debt25——
Lease liabilities (non-current)0.34.25.2
Total liabilities623826
Retained earnings−425−264−136
Shareholders' equity232267−13r
Total liabilities and equity29430575
Shares outstanding60431.3
Cash-flow statement
Depreciation and amortization1.82.11.7
Share-based compensation108.42.2
Cash from operating activities−154−114−52
Capital expenditure−0.0−2.2−0.6
Cash from investing activities40−161−8.8
Shares issued170—
Cash from financing activities14133758
Change in cash2762−3.1
Report10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Kyverna Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 6 · Material agreement 5 · New debt 1 · Shareholder vote 2 · Results announced 9

Kyverna Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Directors and officersResults announced8-K
Material agreement8-K
Results announced8-K
Material agreementNew debt8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Kyverna Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2021$152 MNo. 1$50 to $250 million24equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Kyverna Therapeutics, Inc.#

$50 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.

Lobbying, 2025
$50 K
#1,362 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$320 K
  • Health Issues1 report

Lobbying firms hired in 2025

AKIN GUMP STRAUSS HAUER & FELD $50 K

Kyverna Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$320 K—6
2025$50 K—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Kyverna Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Kyverna Therapeutics, Inc.#

2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $196 K a year.

Certified, FY2026
2
#1,586 among companies on value.today
Worker positions
2
Median wage offered
$196 K
a year, full-time
Applications filed
2
Kyverna Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Associate Director, Medical Engagement OperationsNatural Sciences Managers1$206 K
Associate Director, Program ManagementNatural Sciences Managers1$185 K

Where: Emeryville, CA 2

Kyverna Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202622$196 K2
FY202511$200 K1
FY202311$165 K1
FY202111$135 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Kyverna Therapeutics, Inc.

Discuss Kyverna Therapeutics, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    Kyverna Therapeutics, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $42 million.

  • Mutual funds: 93 funds hold $65 millionautomatic update · Jul 31, 2026

    93 mutual funds in 1 country hold shares of Kyverna Therapeutics, Inc. worth $65 million, about 12.0% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 78 funds added shares and 5 sold; on balance they bought $29 million. Share splits are not counted as trading.

How Kyverna Therapeutics, Inc. compares in Biotechnology

  • Market cap$341 M · higher than 53% of 726
  • Price / book1.5× · lower than 68% of 534
  • FCF yield-45.1% · higher than 26% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Kyverna Therapeutics, Inc.🇺🇸$341 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 1, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Kyverna Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Kyverna Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Kyverna Therapeutics, Inc.? Suggest a correction